(ACET) Adicet Bio - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US0070021086

ACET: Gamma Delta T Cell, CAR Therapies, Cancer, Autoimmune Diseases

Adicet Bio, Inc. is a clinical-stage biotechnology company specializing in the development of allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The companys proprietary platform leverages gamma delta T cells, a unique subset of immune cells with inherent tumor-seeking properties, to engineer chimeric antigen receptor (CAR) T cell therapies. These therapies are designed to enhance persistence and activity in patients, addressing the limitations of traditional autologous CAR T cell therapies. Adicets lead candidate, ADI-001, is an allogeneic gamma delta T cell therapy targeting CD20, currently in Phase I clinical trials for autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkins lymphoma. The company is also advancing ADI-270, an armored gamma delta CAR T cell product candidate targeting CD70, with potential applications in renal cell carcinoma and other CD70+ solid tumor and hematological malignancies. Founded in 2014 and headquartered in Boston, Massachusetts, Adicet Bio is focused on expanding its pipeline to address unmet medical needs in oncology and autoimmune diseases.

Based on the provided and , Adicet Bios stock (NASDAQ:ACET) is currently trading at $0.88 with a 20-day average volume of 1,739,018 shares. The stock is below its 20-day and 50-day simple moving averages (SMA) of $0.93 but remains above its 200-day SMA of $1.24. The Average True Range (ATR) of $0.07 indicates low volatility. From a fundamental perspective, the company has a market capitalization of $71.77 million, with a price-to-book (P/B) ratio of 0.33, suggesting undervaluation relative to its book value. However, the price-to-sales (P/S) ratio of 9.72 reflects a premium valuation relative to its revenue generation. The return on equity (RoE) of -55.73% highlights ongoing losses, typical for early-stage biotechnology companies.

3-Month Forecast: - Price Range: $0.75 - $1.10 - Resistance Levels: $0.93 (20-day SMA), $1.24 (200-day SMA) - Support Levels: $0.75 (projected low based on ATR) - Volume Outlook: Average to below-average volume expected due to low ATR and limited near-term catalysts. - Fundamental Outlook: The companys pipeline progress, particularly updates on ADI-001 and ADI-270, will remain critical drivers of investor sentiment.

Additional Sources for ACET Stock

ACET Stock Overview

Market Cap in USD 72m
Sector Healthcare
Industry Biotechnology
GiC Sub-Industry Health Care Distributors
IPO / Inception 2018-01-26

ACET Stock Ratings

Growth 5y -87.4%
Fundamental -53.4%
Dividend 0.0%
Rel. Strength Industry -60.4
Analysts 4.43/5
Fair Price Momentum 0.47 USD
Fair Price DCF -

ACET Dividends

No Dividends Paid

ACET Growth Ratios

Growth Correlation 3m -49%
Growth Correlation 12m -84.7%
Growth Correlation 5y -76.2%
CAGR 5y -34.91%
CAGR/Max DD 5y -0.36
Sharpe Ratio 12m -2.42
Alpha -75.82
Beta 1.51
Volatility 76.27%
Current Volume 120.3k
Average Volume 20d 381.7k
What is the price of ACET stocks?
As of March 17, 2025, the stock is trading at USD 0.78 with a total of 120,325 shares traded.
Over the past week, the price has changed by +2.57%, over one month by -19.32%, over three months by -18.70% and over the past year by -59.87%.
Is Adicet Bio a good stock to buy?
No, based on ValueRay Fundamental Analyses, Adicet Bio (NASDAQ:ACET) is currently (March 2025) a stock to sell. It has a ValueRay Fundamental Rating of -53.35 and therefor a negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of ACET as of March 2025 is 0.47. This means that ACET is currently overvalued and has a potential downside of -39.74%.
Is ACET a buy, sell or hold?
Adicet Bio has received a consensus analysts rating of 4.43. Therefor, it is recommend to buy ACET.
  • Strong Buy: 5
  • Buy: 0
  • Hold: 2
  • Sell: 0
  • Strong Sell: 0
What are the forecast for ACET stock price target?
According to ValueRays Forecast Model, ACET Adicet Bio will be worth about 0.5 in March 2026. The stock is currently trading at 0.78. This means that the stock has a potential downside of -32.05%.
Issuer Forecast Upside
Wallstreet Target Price 6.4 720.5%
Analysts Target Price 6.4 720.5%
ValueRay Target Price 0.5 -32.1%